MAP2K7 and neoplasm: Yet the observed strong arrest of tumor cells in G1 phase justifies the use of MEK inhibitors as potential cytostatic drugs, and particularly multiple MEK inhibitors are currently being tested in clinical trials Phase I-II (https://www.clinicaltrials.gov).